← All companies

RGEN

Repligen Corporation

RGEN Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$147.06

+3.46 +2.41%

Key statistics

from XBRL data in SEC filings

Market cap

$8.30B

Revenue (TTM)

$785M

Net income (TTM)

$41.5M

EPS (TTM)

$0.74

P/E ratio

198.7

Dividend yield

—

Free cash flow

$93.9M

Cash

$607M

Total assets

$2.95B

Gross margin

26.7%

52-week range

$100.99 – $175.77

Recent SEC filings

40 most recent

Annual, quarterly & current reports

10-Q Quarter ended 2026-06-30 Jul 29, 2026 8-K Results of operations (earnings release) Jul 28, 2026 8-K Entered a material agreement; Results of operations (earnings release); Regulation FD disclosure; Other events Jul 22, 2026 8-K Shareholder vote results May 15, 2026 10-Q Quarter ended 2026-03-31 May 6, 2026 8-K Results of operations (earnings release) May 5, 2026 10-K Fiscal year ended 2025-12-31 Feb 26, 2026 8-K Results of operations (earnings release) Feb 24, 2026 8-K Director or officer change; Regulation FD disclosure Jan 6, 2026 10-Q Quarter ended 2025-09-30 Nov 4, 2025 8-K Results of operations (earnings release) Oct 28, 2025 8-K Director or officer change Sep 2, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Jul 29, 2025 8-K Amended charter or bylaws; Shareholder vote results May 15, 2025 10-Q Quarter ended 2025-03-31 Apr 29, 2025 8-K Results of operations (earnings release) Apr 29, 2025 10-K Fiscal year ended 2024-12-31 Mar 14, 2025 8-K Results of operations (earnings release) Feb 20, 2025 10-Q Quarter ended 2024-09-30 Nov 18, 2024 10-Q/A Quarter ended 2024-06-30 Nov 18, 2024 10-Q/A Quarter ended 2024-03-31 Nov 18, 2024 10-K/A Fiscal year ended 2023-12-31 Nov 18, 2024 10-Q/A Quarter ended 2023-09-30 Nov 18, 2024 10-Q/A Quarter ended 2023-06-30 Nov 18, 2024 10-Q/A Quarter ended 2023-03-31 Nov 18, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Nov 12, 2024 8-K Results of operations (earnings release); Previously issued financials not reliable; Regulation FD disclosure Sep 18, 2024 10-Q Quarter ended 2024-06-30 Jul 30, 2024 8-K Results of operations (earnings release) Jul 30, 2024 8-K Other events Jul 15, 2024 8-K Director or officer change Jun 14, 2024 8-K Regulation FD disclosure Jun 13, 2024 8-K Shareholder vote results May 17, 2024 10-Q Quarter ended 2024-03-31 May 1, 2024 8-K Results of operations (earnings release) May 1, 2024 8-K Director or officer change; Regulation FD disclosure Mar 19, 2024 10-K Fiscal year ended 2023-12-31 Feb 22, 2024 8-K Results of operations (earnings release) Feb 21, 2024 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Dec 15, 2023